Table 3:

Clinical characteristics of the adenocarcinoma group patients before and after matching of propensity score (%)

Characteristics	Before PSM			After PSM
	Preoperative radiotherapy group (n = 142)	Surgery alone group (n = 841)	SMD	Preoperative radiotherapy group (n = 137)	Surgery alone group (n = 140)	SMD
Age (years), n (%)			0.432			0.015
≤66	97 (68.3)	399 (47.4)		92 (67.2)	95 (67.9)
>66	45 (31.7)	442 (52.6)		45 (32.8)	45 (32.1)
Race, n (%)			0.138			0.085
Black	16 (11.3)	71 (8.4)		15 (10.9)	17 (12.1)
White	116 (81.7)	685 (81.5)		112 (81.8)	110 (78.6)
Others	10 (7.0)	85 (10.1)		10 (7.3)	13 (9.3)
Gender, n (%)			0.010			0.004
Male	60 (42.3)	351 (41.7)		57 (41.6)	58 (41.4)
Female	82 (57.7)	490 (58.3)		80 (58.4)	82 (58.6)
Grade, n (%)			0.479			0.095
I	5 (3.5)	91 (10.8)		5 (3.6)	4 (2.9)
II	46 (32.4)	394 (46.8)		46 (33.6)	53 (37.9)
III	89 (62.7)	350 (41.6)		85 (62.0)	82 (58.6)
IV	2 (1.4)	6 (0.7)		1 (0.7)	1 (0.7)
Laterality, n (%)			0.255			0.077
Left	46 (32.4)	376 (44.7))		46 (33.6)	42 (30.0)
Right	96 (67.6)	465 (55.3)		91 (66.4)	98 (70.0)
Stage, n (%)			0.183			0.016
IIIA	127 (89.4)	794 (94.4)		123 (89.8)	125 (89.3)
IIIB	15 (10.6)	47 (5.6)		14 (10.2)	15 (10.7)
Tumour stage, n (%)			0.294			0.036
T1	35 (24.6)	229 (27.2)		35 (25.5)	34 (24.3)
T2	60 (42.3)	439 (52.2)		60 (43.8)	63 (45.0)
T3	32 (22.5)	126 (15.0)		28 (20.4)	28 (20.0)
T4	15 (10.6)	47 (5.6)		14 (10.2)	15 (10.7)
LN examined, n (%)			0.237			0.023
0–9	68 (47.9)	305 (36.3)		64 (46.7)	67 (47.9)
≥10	74 (52.1)	536 (63.7)		73 (53.3)	73 (52.1)
LN positivity, n (%)			0.237			0.013
0–5	106 (74.6)	627 (74.6)		101 (73.7)	104 (74.3)
≥6	36 (25.4)	214 (25.4)		36 (26.3)	36 (25.7)

LN: lymph node; PSM: propensity score matching; SMD: standard mean difference.